Vaccine against streptococcus pneumoniae capsular polysaccharides

Abstract

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to specific advantageous pnumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid aluminium-based adjuvant.

We claim:  
     
         1 . An antigenic composition comprising one or more  Streptococcus pneumoniae  capsular polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid of aluminium-based adjuvants, wherein at least one of the  Streptococcus pneumoniae  polysaccharide conjugates is significantly more immunogenic in compositions comprising 3D-MPL in comparison with compositions comprising 3D-MPL in conjunction with an aluminium-based adjuvant.  
     
     
         2 . The antigenic composition of  claim 1  comprising the  Streptococcus pneumoniae  capsular polysaccharide serotype 4 conjugated to an immunogenic protein.  
     
     
         3 . The antigenic composition of  claim 1  comprising the  Streptococcus pneumoniae  capsular polysaccharide serotype 6B conjugated to an immunogenic protein.  
     
     
         4 . The antigenic composition of  claim 1  comprising the  Streptococcus pneumoniae  capsular polysaccharide serotype 18C conjugated to an immunogenic protein.  
     
     
         5 . The antigenic composition of  claim 1  comprising the  Streptococcus pneumoniae  capsular polysaccharide serotype 19F conjugated to an immunogenic protein.  
     
     
         6 . The antigenic composition of  claim 1  comprising the  Streptococcus pneumoniae  capsular polysaccharide serotype 23F conjugated to an immunogenic protein.  
     
     
         7 . An antigenic composition substantially devoid of aluminium-based adjuvants and comprising 3D-MPL adjuvant and two or more pneumococcal polysaccharide conjugates chosen from the group consisting of: 
 serotype 4;    serotype 6B;    serotype 18C;    serotype 19F; and    serotype 23F.    
     
     
         8 . The antigenic compositions of claims  1 - 7  wherein the  Streptococcus pneumoniae  capsular polysaccharides are conjugated to a protein chosen from the group consisting of: 
 tetanus toxoid;  
 OMPC of  Neisseria meningitidis;    
 diphtheria toxoid;  
 pneumolysin of  Streptococcus pneumoniae ; or  
 CRM197.  
 
     
     
         9 . The antigenic compositions of claims  1 - 7  wherein the  Streptococcus pneumoniae  capsular polysaccharides are conjugated to a protein D of  Haemophilus influenzae.    
     
     
         10 . The antigenic composition of  claim 1  or  7  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 6B, 14, 19F and 23F.  
     
     
         11 . The antigenic composition of  claim 1  or  7  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.  
     
     
         12 . The antigenic composition of  claim 1  or  7  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.  
     
     
         13 . The antigenic composition of  claim 1  or  7  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 3, 4, 5, 6B, 7F, 8, 9V, 12F, 14, 18C, 19F and 23F.  
     
     
         14 . The antigenic composition of  claim 1  or  7  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.  
     
     
         15 . The antigenic composition of  claim 1  or  7  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.  
     
     
         16 . A lyophilsed antigenic composition according to claims  1 - 15 .  
     
     
         17 . The antigenic composition of claims  1 - 16 , which is a vaccine composition.  
     
     
         18 . A method of inducing an immune response to a  Streptococcus pneumoniae  capsular polysaccharide conjugate, said method comprising administering a safe and effective amount of an antigenic composition as claimed herein to a patient.  
     
     
         19 . Use of an antigenic composition as claimed herein in the manufacture of a medicament for the prevention of pneumococcal disease.